Branded

Upsher-Smith's migraine medication Tosymra will now be offered through Cove's telemedicine platform.

Trudhesa is a nasal spray used for the acute treatment of migraine with or without aura in adults.

BeiGene's Brukinsa is now FDA approved for the treatment of adult patients with Waldenström’s macroglobulinemia.

Korsuva for injection is a kappa-opioid receptor agonist that targets the body’s peripheral nervous system.

Tibsovo is the first and only targeted therapy approved for patients with previously treated IDH1-mutated cholangiocarcinoma.

With the addition of three new dosage strengths, Tirosint-SOL is now available in 15 dosage strengths.

The FDA's approval of Keytruda plus Lenvima provides a first-line treatment of adult patients with advanced renal cell carcinoma, the company said.

Welireg is the first treatment for patients with von Hippel-Lindau disease, a genetic condition putting patients at risk of developing several cancers and other types of tumors.

Jardiance is now FDA approved to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction.

Xywav is the first and only FDA-approved treatment for idiopathic hypersomnia, the company said.

The FDA's approval of Nexviazyme gives patients with Pompe disease another enzyme replacement therapy option for this rare disease.

Saphnelo is a monoclonal antibody administered by intravenous infusion to treat lupus.